NEW YORK, November 12, 2013 /PRNewswire/ --
Today, Analysts' Corner announced new research reports highlighting WellPoint, Inc. (NYSE: WLP), Perrigo Company (NYSE: PRGO), Health Net, Inc. (NYSE: HNT), Zoetis Inc. (NYSE: ZTS), and Questcor Pharmaceuticals Inc. (NASDAQ: QCOR). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
WellPoint, Inc. Research Report
On November 7, 2013, WellPoint, Inc. (WellPoint) announced that Julie Goon has been appointed as Senior Vice President of Public Affairs. The Company stated that in her new role, Goon will be responsible for leading WellPoint's state and federal government relations activities, issuing management and policy development, regulatory affairs, and managing the Company's relationships with industry, state, and national associations. According to the Company, Ms. Goon has more than 30 years health care-related policy leadership and management experience and prior to joining WellPoint, she served as Senior Health Policy Director for the U.S. House of Representatives Energy and Commerce Committee. Commenting on the appointment, John Cannon, Executive Vice President, General Counsel, and Chief Public Affairs Officer for WellPoint, said, "Julie's extensive leadership experience in both public and private sectors will be a great asset to our company as we continue to work with and create new partnerships with key public and private stakeholders at both the federal and state level in a post-health care reform marketplace." The Full Research Report on WellPoint, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Perrigo Company Research Report
On November 6, 2013, Perrigo Company (Perrigo) announced that its Board of Directors has declared a quarterly dividend of $0.09 per share. The Company informed that the dividend is payable on December 17, 2013 to shareholders of record as on November 29, 2013. The Full Research Report on Perrigo Company - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Health Net, Inc. Research Report
On November 7, 2013, Health Net, Inc. (Health Net) reported its Q3 2013 financial results. The Company's total revenues decreased 0.2% YoY to $2.8 billion during the quarter. Net income was $66.8 million or $0.83 per diluted share in Q3 2013 compared to net income of $18.0 million or $0.22 per diluted share in Q3 2012. Commenting on the results, Jay Gellert, Health Net's CEO, said, "We continue to achieve significant milestones in our preparations for the compelling opportunities in front of us in 2014 and beyond. With this in mind, we know that it is important that we continue to produce consistent operating performance in 2013. We believe that our 2013 third quarter results demonstrated that we are on track to do so. We expected some resolution of our California Medicaid settlement process in 2013. The rate adjustments that occurred in the third quarter of 2013 will help compensate for general and administrative spending in the fourth quarter as we prepare for 2014. For the full year 2013, we are maintaining our GAAP earnings per diluted share guidance of $2.10 to $2.20 and our guidance of $2.20 to $2.30 per diluted share for the combined Western Region and Government Contracts segments." The Full Research Report on Health Net, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Zoetis Inc. Research Report
On November 5, 2013, Zoetis Inc. (Zoetis) reported its Q3 2013 financial results. The Company's total revenue increased 8.2% YoY to $1.1 billion during the quarter. Net income attributable to Zoetis was $131 million or $0.26 per diluted share compared to $162 million or $0.32 per diluted share in Q3 2012. Commenting on the results, Zoetis CEO Juan Ramón Alaix, said, "With three quarters now reported in our first year, I am pleased with how we are meeting our commitments to customers, delivering financial results and setting a solid foundation for our future. We continue to build on the commercial performance, innovative R&D and reliable supply chain that have been critical to our success, while managing through all the changes that come with standing up a new company." For full-year 2013 the Company anticipates to achieve revenue ranging between $4,475 million and $4,525 million and diluted EPS in the range of $0.98 and $1.02. The Full Research Report on Zoetis Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Questcor Pharmaceuticals Inc. Research Report
On November 7, 2013, Questcor Pharmaceuticals Inc. (Questcor) announced that the Company's Executive Management will present at the 2013 Credit Suisse Annual Healthcare Conference in Scottsdale, Arizona, on November 14, 2013 at 11:00 a.m. ET/8:00 a.m. PT. The Company informed that a live webcast and archived replay of the presentation will be available on the Events & Presentations section of its Investor Relations website for approximately 90 days after the Conference. The Full Research Report on Questcor Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
- For any urgent concerns or inquiries, please contact us at [email protected].
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Namrata Maheshwari, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts' Corner